VLP Therapeutics Raises $16 Million Series A Funding For Cancer Treatment Vaccine

VLP Therapeutics, a US-based biopharmaceutical company founded in 2013, announced on Monday that it has secured Series A funding worth $16 million from investors such as MIYAKO Capital and Konishiyasu Capital.

The biotech company is deeply engaged in the development and research of cancer treatment vaccines through their exclusive technologies. Led by Dr. Wataru Akahata, they have a mission to address unmet medical needs around the world and provide more vaccine treatment, not just cancer but other prophylactics against dengue, malaria, and coronavirus.

On the 1st of October, 2020, Fujifilm Holdings Corp concluded a manufacturing agreement for the formulation of Covid vaccine with VLP Therapeutics.

The company, on Monday, onboarded Miwa Toyoda, as chief business officer. Miwa Toyoda is a venture capitalist who previously specialized in pharmacy and biotech. VLP expects she'll be instrumental to the company and further boost its vaccine development and research projects, as well as broaden its portfolio.